Quinuclidine derivatives and medicinal compositions containing the same

1. A powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X − is associated with the positive charge of the nitrogen atom and wherein X − is a pharmaceutically acceptable anion of a mono- or polyvalent acid.

2. The powder inhalant of claim 1 further comprising a pharmaceutically acceptable carrier or diluent.

3. The powder inhalant of claim 2 wherein the pharmaceutically acceptable carrier or diluent is lactose.

4. The powder inhalant of claim 1 further comprising a β 2 agonist.

5. The powder inhalant of claim 4 further comprising a steroid or a phosphodiesterase IV inhibitor.

6. The powder inhalant of claim 1 further comprising a steroid.

7. The powder inhalant of claim 6 further comprising a phosphodiesterase IV inhibitor.

8. The powder inhalant of claim 1 further comprising a phosphodiesterase IV inhibitor.

9. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective amount of the powder inhalant of claim 1 .

10. The method of claim 9 further comprising administering an effective amount of a β 2 agonist.

11. The method of claim 10 further comprising administering an effective amount of a steroid or a phosphodiesterase IV inhibitor.

12. The method of claim 9 further comprising administering an effective amount of a steroid.

13. The method of claim 12 further comprising administering an effective amount of a phosphodiesterase IV inhibitor.

14. The method of claim 9 further comprising administering an effective amount of a phosphodiesterase IV inhibitor.